🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSide Effects & ManagementPancreatitis risk assessment — pooled safety analysis

Pancreatitis risk assessment — pooled safety analysis

Dr.MetabolicMD Sun, Jun 7, 2026 at 2:11 AM 15 replies 291 viewsPage 1 of 3
Dr.MetabolicMD
VIP Member
2,345
16,789
Jan 2024
Rochester, MN
Jun 7, 2026 at 2:11 AM#1

This gets cited here weekly, usually second-hand, so it is worth setting out what it does and does not establish.

Pooled safety analyses have not shown a clear excess of pancreatitis for this class, and the background rate in the population being treated is already elevated by obesity, gallstones and alcohol. That said, the labels carry the warning, and the presentation is distinctive enough to act on: severe persistent upper-abdominal pain radiating to the back, usually with vomiting, not relieved by anything.

Where I think it is weakest: the follow-up is short relative to how long people actually take these drugs, so durability is an assumption here rather than a finding.

So the question, as narrowly as I can put it: what the pooled safety data actually shows for this class, as opposed to what the label warning implies. Not looking for reassurance. Looking for the part I have got wrong.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
16 11SleepDoc_PDX, RegAffairsDC, BiostatsBrad and 13 others
Reply Quote Save Share Report
BethLabQueen
Senior Member
1,234
5,678
May 2024
Virginia
Online
Jun 7, 2026 at 2:13 AM#2
Dr.MetabolicMD said:
Pooled safety analyses have not shown a clear excess of pancreatitis for this class, and the background rate in the population being treated is…

Pancreatitis scare with pancreatitis risk: had severe upper abdominal pain radiating to my back at week 11. Went to the ER — they checked lipase and amylase, both normal. Turned out to be a gallstone.

But I'm glad I went. The risk of pancreatitis, while small (<0.5%), is real. Don't try to tough out severe abdominal pain on a GLP-1 agonist. Get checked.

Last edited: Jun 7, 2026 at 3:13 AM
15 10Dr.PulmRoch, maya_sedona, stefan_berlin and 12 others
Reply Quote Save Share Report
Dr.SleepRoch
Senior Member
1,123
5,678
Apr 2024
Rochester, MN
Jun 7, 2026 at 2:14 AM#3
Dr.MetabolicMD said:
Pooled safety analyses have not shown a clear excess of pancreatitis for this class, and the background rate in the population being treated is…

Lipase monitoring while on pancreatitis risk: my doctor checks lipase every 3 months given the theoretical pancreatitis risk. All readings have been normal:

  • Baseline: 35 U/L
  • Month 3: 33 U/L
  • Month 6: 33 U/L
  • Month 9: 35 U/L

Normal range is 0-160 U/L. While clinical pancreatitis is rare (<0.5%), I find peace of mind in regular monitoring. Worth asking your doctor about if you're on a GLP-1 long-term.

Last edited: Jun 7, 2026 at 6:14 AM
14 9Dr.NephBHM_UK, kim_atl_prep, sarah_TO and 11 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
Dr.KarenChen
VIP Member
4,210
24,567
Nov 2023
San Francisco, CA
Jun 7, 2026 at 2:16 AM#4

Answering the narrow version, because the broad one does not have a single answer. Start from the measurement rather than the conclusion. Almost every disagreement here turns out to be two people measuring different things and comparing the numbers anyway.

13 8mike.trainer_LA, sarah_nash92, FitDadDave and 10 others
Reply Quote Save Share Report
paige_pharma
Member
289
1,234
Sep 2024
Omaha, NE
Jun 7, 2026 at 2:25 AM#5
BethLabQueen said:
Pancreatitis scare with pancreatitis risk: had severe upper abdominal pain radiating to my back at week 11.

Adding a me-too, because a thread of one person's experience is not much use. I had assumed I was the exception until I read this.

12 7lucas_SP_BR, lisa_labSD, adam_van and 9 others
Reply Quote Save Share Report

Similar Threads

Nausea incidence by dose tier — STEP and SURMOUNT meta-analysis16 replies
Constipation on GLP-1: pathophysiology and fiber protocol5 replies
Alopecia on GLP-1 — telogen effluvium differential diagnosis3 replies
Gallbladder disease risk — cholelithiasis data from clinical trials12 replies
Fatigue on semaglutide — caloric deficit vs direct drug effect25 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register